Project
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Automatically Closed · 2020 until 2022
Rothermundt Christian, Aeppli Stefanie, Fischer Stefanie, Omlin Aurelius
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2020
End Date
2022
Financing
Industry
Study Design
Phase II
Brief description/objective
Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozantinib